Tuesday, March 19, 2024

Sputnik-V vaccine arrives in India for clinical trials: Coronavirus





The Russian vaccine for tackling the Wuhan virus infection, Sputnik-V, has arrived in India for Phase 2/3 clinical trials. The vaccine is being handled by Dr Reddy’s Laboratories of Hyderabad which has been given permission for these trials.

The manufacturers of Sputnik-V, the Gamaleya National Research Institute of Epidemiology and Microbiology, have claimed 92% efficacy of the vaccine. Generally, vaccines are given the go-ahead for human usage by regulating agencies after reaching a minimum of over 50% efficacy.

Drug Controller General of India (DCGI) has permitted the human trials of a couple of other vaccines also. Russia was the first country in the world to have succeeded in making a vaccine for controlling Covid-19. However, small sample size and other such issues were raised by the medical fraternity.

The buzz about the vaccine has been created on the Social Media as a video with the labels of Sputnik-V went viral. Some reports then confirmed that the vaccine has indeed arrived in India.


Read More

Support Us
Contribute to see NewsBred grow. And rejoice that your input has made it possible.